Quest Diagnostics Incorporated ($DGX) Stock Forecast: Up 7.3% Today

What is Quest Diagnostics Incorporated?

Quest Diagnostics (DGX) Market: Quest Diagnostics (DGX) had a strong bullish movement today, reaching a new 52-week high and hitting an all-time high at $198.00.

Why is Quest Diagnostics Incorporated going up?

DGX stock is up 7.3% on Feb 10, 2026 20:40

• Quest Diagnostics reported better-than-expected Q4 2025 revenue and earnings, surpassing analyst estimates and providing an optimistic outlook for full-year 2026.
• The company's strong financial performance, including a 7.1% increase in revenue and a dividend hike, fueled investor confidence and positive market sentiment, leading to the stock's surge.
• Despite slightly lower FY 2026 earnings guidance compared to consensus estimates, the robust Q4 results and positive outlook overshadowed this concern, driving the stock to new highs.
• Quest Diagnostics' consistent dividend payments, strong revenue growth, and increased operating margins contributed to the bullish momentum, despite some warnings of the stock being slightly overvalued.

DGX Price Chart

DGX Technical Analysis

DGX News

Quest's (NYSE:DGX) Q4 CY2025: Beats On Revenue

Quest Diagnostics (NYSE:DGX) reported better-than-expected Q4 CY2025 revenue of $2.81 billion, up 7.1% year-on-year, and non-GAAP EPS of $2.42, beating analyst estimates. The company also provided optimistic full-year revenue guidance and increased its quarterly dividend. Despite robust recent growth, the company's five-year revenue and EPS growth have been modest, with operating margins declining.

https://finviz.com/news/305417/quests-nyse-dgx-q4-cy2025-beats-on-revenue

Quest Diagnostics hits 52-week high on outlook (DGX:NYSE)

Quest Diagnostics (DGX) shares reached a new 52-week high after the diagnostic services provider surpassed Q4 2025 financial forecasts and provided a 2026 outlook that exceeded consensus expectations. The company also announced a dividend hike.

https://seekingalpha.com/news/4549561-quest-diagnostics-hits-52-week-high-on-outlook

Quest Diagnostics' Q4 Earnings & Revenues Beat Estimates, Stock Up

Quest Diagnostics (DGX) reported better-than-expected earnings and revenues for the fourth quarter of 2025, with adjusted EPS of $2.42 and revenues of $2.81 billion, both surpassing consensus estimates. The company's Diagnostic Information Services revenues saw a 7.3% increase, and volumes were up 8.5% year-over-year. Quest Diagnostics also provided a positive outlook for full-year 2026 revenues and adjusted EPS, contributing to a nearly 2% gain in pre-market trading for DGX shares.

https://www.tradingview.com/news/zacks:334837347094b:0-quest-diagnostics-q4-earnings-revenues-beat-estimates-stock-up/

Quest Diagnostics stock hits all-time high at $198.00 By Investing.com

Quest Diagnostics (DGX) stock has reached an all-time high of $198.00, driven by strong investor confidence and positive market sentiment. The company, with a market capitalization of $21.6 billion, has seen its stock increase by 18.51% over the past year and maintained dividend payments for 23 consecutive years. Recent quarterly results surpassed expectations, contributing to the optimistic outlook despite analyst warnings of the stock being slightly overvalued.

https://in.investing.com/news/company-news/quest-diagnostics-stock-hits-alltime-high-at-19800-93CH-5232186

Quest Diagnostics (NYSE:DGX) Issues FY 2026 Earnings Guidance

Quest Diagnostics (NYSE:DGX) has issued its FY 2026 earnings guidance, projecting an EPS of 9.45-9.65, which is below the consensus estimate of 10.41. Despite this, the company reported strong Q4 results, beating analyst estimates for both EPS and revenue. Insider selling was noted, but analysts maintain an average "Moderate Buy" rating with a target price of $198.50.

https://www.marketbeat.com/instant-alerts/quest-diagnostics-nysedgx-issues-fy-2026-earnings-guidance-2026-02-10/

Trending Today

Heating Oil ($HEATOIL) Commodity Forecast: Up 6.1% Today

QTUM ($QTUM) Crypto Forecast: Down 6.0% Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

Acuity Brands Inc. ($AYI) Stock Forecast: Down 5.2% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.3% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Down 7.6% Today

Lam Research Corporation ($LRCX) Stock Forecast: Down 8.6% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.3% Today

Intel Corporation ($INTC) Stock Forecast: Down 6.4% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.2% Today

Quest Diagnostics Incorporated Price History

02.09.2025 - DGX Stock was down 5.0%

• Today, despite collaborations with Epic and Rutgers Cancer Institute, DGX encountered a downward movement.
• Speculations suggest the market response could be influenced by overall market trends, sector shifts, or profit collection by traders.
• Some investors might have been anticipating swift financial gains from the partnerships, potentially triggering a temporary stock sell-off.
• Observing the progress of these collaborations is crucial to evaluate their influence on DGX's financial results and stock valuation.

21.09.2025 - DGX Stock was down 2.7%

• Despite surpassing Q3 earnings and revenue estimates, Quest Diagnostics (DGX) experienced a bearish movement in the market today.
• The market might have reacted negatively due to profit-taking by investors after the recent positive performance.
• Investors may have been expecting even higher results, leading to a sell-off post-earnings announcement.
• The stock's strong bearish movement could also be influenced by broader market conditions or sector-specific factors impacting healthcare companies.

10.01.2026 - DGX Stock was up 6.8%

• Despite issuing lower-than-expected earnings guidance for FY 2026, Quest Diagnostics reported impressive Q4 results, surpassing analyst estimates for both EPS and revenue.
• The company's decision to increase its quarterly cash dividend by 7.5% and add $1 billion to its buyback program showcases its commitment to enhancing shareholder value and confidence in its financial strength.
• Quest Diagnostics' strong financial performance, optimistic revenue guidance, and strategic initiatives such as expanding collaborations and delivering clinical innovations have likely contributed to the bullish market movement, overshadowing concerns about the lower earnings guidance for the upcoming fiscal year.

10.01.2026 - DGX Stock was up 5.4%

• Quest Diagnostics (DGX) stock reached a new 52-week high and all-time high of $198.00, experiencing a strong bullish movement.
• The company's robust Q4 2025 financial results exceeded earnings and revenue estimates, contributing to the bullish trend. A positive outlook for 2026 further bolstered investor confidence.
• Despite slightly lower-than-expected FY 2026 earnings guidance, the strong quarterly performance and optimistic full-year revenue forecast overshadowed this concern.
• Investor confidence was also boosted by a dividend hike announcement and the company's history of consistent dividend payments, driving the stock price higher.

10.01.2026 - DGX Stock was up 7.3%

• Quest Diagnostics reported better-than-expected Q4 2025 revenue and earnings, surpassing analyst estimates and providing an optimistic outlook for full-year 2026.
• The company's strong financial performance, including a 7.1% increase in revenue and a dividend hike, fueled investor confidence and positive market sentiment, leading to the stock's surge.
• Despite slightly lower FY 2026 earnings guidance compared to consensus estimates, the robust Q4 results and positive outlook overshadowed this concern, driving the stock to new highs.
• Quest Diagnostics' consistent dividend payments, strong revenue growth, and increased operating margins contributed to the bullish momentum, despite some warnings of the stock being slightly overvalued.

23.06.2025 - DGX Stock was down 0.6%

• Despite surpassing Q2 earnings and revenue estimates, Quest Diagnostics (DGX) witnessed a bearish market movement.
• The market potentially reacted negatively due to profit-taking by investors following a 3.2% rise in pre-market trading post the positive earnings results.
• Investors might have anticipated higher numbers or future guidance, leading to a sell-off after the earnings announcement.
• The robust historical performance of Quest Diagnostics possibly elevated expectations to a level where meeting estimates was insufficient to maintain the bullish momentum, resulting in today's bearish movement.

22.06.2025 - DGX Stock was up 5.2%

• Over the past 5 years, Quest Diagnostics (DGX) has delivered impressive performance, surpassing the market with an average annual return of 508.21%.
• The positive market movement of Quest Diagnostics is possibly influenced by expectations of beating earnings estimates in the upcoming report.
• Investor sentiment towards Quest Diagnostics remains upbeat due to its solid historical performance and growth potential in the diagnostic testing sector.

21.04.2025 - DGX Stock was down 5.1%

• Today's decline in DGX's stock price could be linked to profit-taking by investors following the recent surge.
• The market reaction might be influenced by broader economic conditions or specific news affecting the healthcare sector, resulting in a temporary downturn for DGX.
• Investors may be reevaluating their positions in DGX after the recent uptrend, causing a short-term decrease in the stock price.

02.01.2026 - DGX Stock was down 1.0%

• The bearish movement in Quest Diagnostics (DGX) stock today could be attributed to several factors:
• The launch of a new ultrasensitive blood test for measurable residual disease (MRD) in multiple myeloma patients by Quest Diagnostics may have raised concerns about potential competition in the diagnostic testing market, impacting investor sentiment.
• The significant increase in stake by AlphaQuest LLC in Quest Diagnostics, coupled with company insiders selling off stock, might have led to uncertainty among investors about the company's future performance.
• Despite receiving a "Moderate Buy" consensus rating from analysts and positive price target revisions, the overall market sentiment towards Quest Diagnostics may have been overshadowed by the news of new product launches and insider selling activities.

22.03.2025 - DGX Stock was up 7.7%

• Quest Diagnostics (DGX) stock showed a strong bullish movement.
• The company surpassed expectations with its first quarter 2025 earnings and revenues, outperforming analyst projections.
• The stock's upward trend can be attributed to the favorable earnings report and sustained growth over the past 5 years.
• Investor optimism in Quest Diagnostics' performance and market position is likely driving the stock price increase.

22.06.2025 - DGX Stock was up 6.0%

• Quest Diagnostics (DGX) exceeded Q2 earnings and revenue estimates, showcasing a 15.2% revenue growth and a significant EPS beat, leading to a 3.2% rise in the stock price.
• The company's consistent outperformance over the past 5 years, with an impressive annualized return of 508.21%, has likely contributed to investor confidence and positive market sentiment.
• With a history of surpassing earnings expectations and favorable market conditions, Quest Diagnostics (DGX) appears well-positioned to continue its upward trajectory, attracting further investor interest and driving the bullish movement in the stock price.

01.09.2025 - DGX Stock was down 3.7%

• The partnership between DGX's Haystack Oncology and Rutgers Cancer Institute to study the application of ctDNA MRD test in guiding therapy for lung cancer could have raised concerns about the company's current testing methods or future revenue streams.
• Investors might be worried about the potential impact on DGX's market share or competitive position in the oncology diagnostic testing space.
• The market might be reacting to the uncertainty surrounding the outcome of the study and its implications for DGX's future growth prospects in the oncology segment.